People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gloucester Pharmaceuticals Inc | — | Biotechnology | Series B | $26.0M | $806.7M | 2009 |
Nicholas Vrolijk at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nicholas Vrolijk on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Seth Harrison | 1 | 19 |
| David Schnell | 1 | 7 |
| Thomas Dyrberg | 1 | 5 |
| Jay Moorin | 1 | 4 |
| Donald J Hayden | 1 | 3 |
| Alan B. Colowick | 1 | 3 |
| Martin Vogelbaum | 1 | 3 |
| Jean C. Nichols | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.